CRESCENT BIOPHARMA, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
CRESCENT BIOPHARMA, INC. (CBIO) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 7.23 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-07-30
- CRESCENT BIOPHARMA, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-06-30 was 7.23M shares, a 67.98% increase year-over-year.
- CRESCENT BIOPHARMA, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 7.00M shares, a 9.24% increase year-over-year.
- CRESCENT BIOPHARMA, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-09-30 was 4.63M shares.
- CRESCENT BIOPHARMA, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 4.31M shares.
- CRESCENT BIOPHARMA, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 7.01M shares.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 0 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 7.23M shares 10-Q · filed 2026-07-30 | 7.23M shares 10-Q · filed 2026-07-30 | |||
| 2026-03-31 | 7.00M shares 10-Q · filed 2026-04-29 | ||||
| 2025-12-31 | 7.01M shares 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | 4.63M shares 10-Q · filed 2025-11-06 | 4.63M shares 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | 4.31M shares 10-Q · filed 2026-07-30 | 4.31M shares 10-Q · filed 2026-07-30 | |||
| 2025-03-31 | 6.41M shares 10-Q · filed 2026-04-29 | ||||
| 2024-12-31 | 4.22M shares 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | 20.19M shares 10-Q · filed 2025-11-06 | ||||
| 2020-06-30 | 6.43M shares 10-Q · filed 2020-07-31 | 6.43M shares 10-Q · filed 2020-07-31 | |||
| 2019-06-30 | 5.07M shares 10-Q · filed 2020-07-31 | 5.07M shares 10-Q · filed 2020-07-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |